Mission:Harnessing the power of the immune system to develop groundbreaking therapies for cancer and aging.
Vision:A future where immunotherapy transforms patient outcomes with safer, more effective treatments.
Theravac Bio was established in Australia in 2024. As a biotech company, it dedicated to the innovation and development of next-generation immunotherapies targeting tumor and Immuno- senescence.
Product-Project Pipeline
Theravac Bio' immune intervention strategies are comprised of two programs: Therapeutic tumor vaccine and reconstruction of Immune homeostasis to promote health.
Research & Development
Program A: Therapeutic tumor vaccine.
Therapeutic tumor vaccine: Aim to enhance the immunogenicity, activate the patient's immune system inducing both T-cells and humoral immune responses, thus controlling or
removing the tumor.
The major product: Lung cancer vaccine.
Indication: Treatment of patients with Non-Small Cell Lung Cancer (NSCLC).
Current R&D stage: The results of the preclinical pharmacodynamic studies on the therapeutic lung cancer vaccine indicate that the vaccine can induce high levels of T-cell immune responses against lung cancer antigens. Its therapeutic effect on lung cancer has
been well verified in the therapeutic mouse lung tumor model. The vaccine is being loped in a Phase I clinical trial.
Program B: Reconstruction of Immune homeostasis
The immune system including innate immunity and adaptive immunity, has the functions of immune surveillance, immune defence, and self-regulation, which can maintain immune
homeostasis and the life health. However, nearly 70% of population are in sub health status according to the WHO report,which could be partially ascribed to the immunosenescence.
Natural killer T cells (NKT cells) are a group of special T cell subsets that can bridge innate immunity and acquired immunity,which express both T cell receptor TCR and molecular markers of NK cells on the cell surface. Type 1 NKT cells also known as
invariant natural killer T cells (iNKT),can specifically boost immune homeostasis through enhancing immune response, regulating inflammation and metabolism.
Our primary IIT study results showed that the people could benefit from infusion of iNKT cells, such as reconstructing immune homeostasis and better control blood sugar and
lipids,and ultimately improving sub-health status.
The program is being developed in a Phase I/II clinical trial.
Board of Directors
-
Responsible for formulating corporate development strategies,building high-end talent teams, and overseeing overall corporate
operations management as well as investment and financing activities.
Mr. Qian received advanced executive management training in the United States and possesses 30 years of experience in entrepreneurship and operations management. Mr. Qian has good insight in the complex business environment. He possesses the outstanding ability of decision making in time and led the enterprise in the continuous innovation and development. He is good at strengthening risk management mechanism, and collaborative innovation to maintain the competitiveness, flexibility and tenacity of the enterprises.
Over the past five years, Mr. Qian has focused on the field of oncology therapeutics and anti-aging industries. He founded TheraVac Biotech, assembling a team of internationally renowned experts in immunotherapy and vaccinology, including researchers from Fudan University and the University of Melbourne. Mr. Qian also established a dedicated industry fund investing in biopharmaceutical projects while strategically planning for global expansion. He built an international collaboration network spanning Australia, China, and the U.S., laying the foundation for future global market entry. These efforts contribute to enhancing Australia's biopharmaceutical influence, promoting the development of Victoria's life sciences cluster, and improving population health outcomes. -
Responsible for the Innovative Research and Product Development
Dr. Jianqing Xu had led the tumor therapeutic vaccines R&D team.As the CSO, Dr.Xu will focus on the design of innovative immunogen and proof of the concept. He will also involve in the establishment of pilot manufactural process including construct of the seed bank; majorly aims to GMP process development and the establishment of quality control system, as well as preclinical safety evaluation study. He will also pay attention to the clinical study.
Dr. Jianqing Xu graduated from China Medical University and received his Ph.D. from Peking Union Medical College. He had been appointed as an assistant professor at Department of Microbiology and Immunology, Georgetown University in 2001. At present,Dr.Jianqing Xu is the tenured professor in Fudan University. -
Responsible for the GMP manufacture and Clinical study
Dr. Zhang will collaborate with Chief Scientist on GMP process development and the establishment of quality control system. She will devote more efforts to implement the clinical trials to investigate the safety and effectivity of the tumor therapeutic vaccines.
Dr. Xiaoyan Zhang obtained her MD degree at Harbin Medical University in China, and PhD degree at Kyoto University in Japan. She had been appointed as an assistant professor at Tohoku University in Japan, and assistant scientist in the Medical Center, New York University. At present, Dr.Zhang is the tenured professor in Fudan University.-
He has 3+ years 'working experience on Creating SPAC & acquired the assets from MNC,and 18+ years' experience in leading international pharmaceutical companies for Business Development, Regulatory Affairs and License/Technology Transfer. He has rich experience in M&As, setting up JV and intergradation, in/out licensing deals. Especially, he was successful got import permissions approval in recent years, He is widely connection with pharmaceutical industry and experience for introducing China innovation to emerge market.
-
Our Team
Our team, led by esteemed professors from Fudan University, is composed of experts with deep expertise in immunology, clinical medicine, and biotechnology R&D. Many team
members have extensive international experience, bringing global perspectives and cuttingedge insights to our work.
With over 30 years of experience, they have established a strong track record in scientific innovation and clinical translation. The team hold more than 60 invention patents and have
made impactful contributions in areas such as immunotherapy, vaccine development, and diagnostic technologies. The core strength lies in transforming advanced research into
effective, real-world medical solutions.
In collaboration with the innovative scientists team from Fudan University, we will create a comprehensive facility that includes R&D laboratories, and GMP manufactural platforms. We aim to raise the standard of immunotherapy in Australia to new international heights,earning recognition for advancing global best practices and delivering patient-centric innovation.
Corporate Governance
Theravac Bio adheres to the corporate governance principles set out in the MiddleNext Code of Governance for Mid and Small Caps (Code de gouvernement d'entreprise des valeurs moyennes et petites de MiddleNext). This Code, developed by MiddleNext—an independent association representing mid-sized publicly listed companies—serves as a widely recognized framework for promoting transparent, responsible, and effective governance tailored to the specific needs of small and mid-cap firms.
Ethics &
Compliance
Theravac Bio is committed to conducting its operations with integrity and in strict compliance with all applicable legal and regulatory frameworks.
To uphold these standards, Theravac Bio has implemented a comprehensive compliance program that encompasses business ethics and personal data protection, and includes
dedicated tools such as a whistleblowing mechanism.
Collaborations
We engage in exchanges and partnerships to strengthen our R&D capabilities, expand our product portfolio, and enhance our processes. Theravac Bio collaborates with both public and private partners in China and internationally across several joint programs.
上海复旦附属肿瘤医院
上海金山公共卫生中心